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■ CASE REPORT ■
Introduction
Both transient and permanent ovarian failure is com-
mon among women surviving various kinds of hemato-
logic malignancies. Several reports have described the
frequency of ovarian failure in women with Hodgkin dis-
ease or non-Hodgkin diseases, with rates ranging from
40% to 90% following chemotherapy regimens [1]. Since
ovarian failure commonly occurs after chemotherapy,
menopause or related sexual activity is often overlooked.
We report a case that emphasizes a clinically rare compli-
cation, the complete obliteration of the vagina. The
patient died of sepsis and relapse of the underlying
malignancy.
Case Report
A 42-year-old married woman had suffered from
abdominal pain and spiking fever for days. She had
Mayer-Rokitansky-Küster-Hauser syndrome (absence of
the uterus, cervix and vagina). A neovagina was estab-
lished 20 years previously for the purpose of marriage,
and she had normal sexual activity thereafter. Sexual
activity stopped 1 year prior to this admission, because
a cutaneous T-cell lymphoma (stage T4: generalized
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SUMMARY
Objective: Although ovarian failure commonly occurs following chemotherapy, the relation between menopause
or related sexual activity in this failure is often overlooked. We report a case that emphasizes a clinically rare com-
plication, the complete obliteration of the vagina.
Case Report: A 42-year-old married woman with a history of Mayer-Rokitansky-Küster-Hauser syndrome, an
established neovagina, and complete clinical remission of cutaneous T-cell lymphoma (stage T4) treated with
bleomycin, cyclophosphamide, doxorubicin, vincristine and prednisolone had suffered from abdominal pain.
Imaging studies (computed tomography) and laboratory evaluations indicating a suspicious pelvic abscess with
leukocytosis (16,800/mm3) and elevated serum C-reactive protein (18.4 mg/L) levels. The patient underwent
intensive medical treatment and surgical intervention, but died 2 months later. Pathology showed widespread lym-
phoma throughout the perineal area, including the neovagina, deep pelvic cavity and the entire abdominal cavity.
Conclusion: Physicians should be greatly concerned about the frequency and severity of treatment-associated
acute and long-term complications, such as gonadal toxicity. In this case, vaginal obliteration was an early sign
of tumor recurrence, although menopause may have contributed to the vaginal obliteration. [Taiwan J Obstet
Gynecol 2010;49(1):69–71]
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erythroderma [2]) was diagnosed. She was treated
with bleomycin, cyclophosphamide, doxorubicin, vin-
cristine, and prednisolone. Before treatment, the gyne-
cologic consultation was unremarkable and the
Papanicolaou test was negative for malignant cells.
After half a year of treatment, complete clinical remis-
sion was achieved, but the woman suffered from
severe vasomotor syndromes, including hot flashes,
insomnia and night sweating. Hormone profile evalua-
tion showed menopause with an estrogen level of
<20 pg/mL and a follicle-stimulating hormone level of
>30 IU/mL. Neither gynecologic examination nor hor-
mone replacement therapy was performed. She had
been in good health and regularly followed up until
this admission. At this hospitalization, imaging studies
(computed tomography) and laboratory evaluations
indicated a suspicious pelvic abscess with leukocytosis
(16,800/mm3) and elevated serum C-reactive protein
(18.4 mg/L) levels. Empirical antibiotics, including
clindamycin and gentamicin, were prescribed. Surgical
intervention and drainage were implemented because
of exacerbation of the clinical course, including spiking
fever and progressive abdominal pain after a 2-week
treatment with antibiotics, and the strong recommenda-
tion of infection specialists. Exploratory laparotomy was
performed 18 days after admission. This procedure
showed severe adhesion in the visceral organs of the
abdominal cavity. Random biopsy, including adhesion
lysis, and culture were performed. However, the suspi-
cious abscess was not found during operation. The
surgical position of the patient was changed from the
supine to the lithotomy position to evaluate the deep
pelvic cavity. A complete distal vaginal obliteration was
noted after identification of the vulva opening. A
probe and knife were used to dissect the occluded
neovagina bluntly and sharply, and then a Hegar dila-
tor was used to establish the neovaginal channel from
the distal end (site of obliteration) to the vaginal stump.
A purulent whitish to yellowish discharge flew out from
an abscess in the vaginal stump area (proximal end of
the reconstructed vagina). A sump drainage system was
employed for drainage, and the abdominal wall was
closed as usual. Although the patient underwent
aggressive medical treatment after surgery, she died 2
months later. Pathology showed widespread lymphoma
throughout the perineal area, including the neovagina,
deep pelvic cavity and the entire abdominal cavity.
Discussion
Since the introduction of aggressive chemotherapy,
alone and in combination with irradiation, long-lasting
remissions and cures have been obtained in patients
with hematologic malignancies. Therapy-induced
gonadal toxicity has become an issue of clinical concern
to these patients [1]. Gonadal injury may not only
result in reduced fertility but also affect gonadal
steroid synthesis, which may be associated with car-
diovascular, sexual and emotional disorders. Instances
of successful pregnancy after curing hematologic malig-
nancies have occasionally been reported [3,4]. The use
of hormone replacement therapy or oral contracep-
tives to protect ovarian function is still controversial;
however, hormone replacement therapy may be benefi-
cial in young women with therapy-induced menopause
[4]. This benefit has yet to be addressed with addi-
tional clinical observation. To date, only one reported
case has discussed vaginal obliteration after curing a
hematologic malignancy [5]. Survival seems to be the
priority when physicians manage patients with life-
threatening diseases such as hematologic malignancies.
However, concern about the frequency and severity of
treatment-associated acute and long-term complica-
tions such as gonadal toxicity should be emphasized.
Management recommendations for these patients
should be in accordance with the available evidence.
Unfortunately, only rare reports have focused on this
aspect of patient management [5–8].
This case of vaginal obliteration may have been
caused by chemotherapy-induced gonadal toxicity and a
subsequent vaginal defect and occlusion, concomitant
lymphoma infiltration of the vaginal wall, or a combina-
tion of severe bacterial or fungal infections. We could
not determine which factor was the initiator, but
menopausal status was important. Of course, severe
infection and lymphoma infiltration contributed to
these complications.
In summary, physicians should be greatly concerned
about the frequency and severity of treatment-associated
acute and long-term complications, such as gonadal
toxicity. All efforts, including simultaneously using a
gonadotropin-releasing hormone agonist [9] should
be attempted to minimize the gonad failure-related
sequelae [10,11], even if the cancer in the patients has
been successfully treated. In this case, vaginal oblitera-
tion was an early sign of tumor recurrence, although
menopause may have contributed to this problem.
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